Wall Street analysts expect Alpine Immune Sciences Inc (NASDAQ:ALPN) to report ($0.62) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Alpine Immune Sciences’ earnings, with the lowest EPS estimate coming in at ($0.80) and the highest estimate coming in at ($0.48). Alpine Immune Sciences reported earnings of ($0.38) per share in the same quarter last year, which would suggest a negative year-over-year growth rate of 63.2%. The firm is scheduled to announce its next quarterly earnings results on Monday, May 13th.
On average, analysts expect that Alpine Immune Sciences will report full year earnings of ($2.71) per share for the current financial year, with EPS estimates ranging from ($3.68) to ($2.10). For the next financial year, analysts anticipate that the company will post earnings of ($2.19) per share, with EPS estimates ranging from ($2.45) to ($1.84). Zacks’ earnings per share averages are a mean average based on a survey of research firms that follow Alpine Immune Sciences.
Alpine Immune Sciences (NASDAQ:ALPN) last announced its earnings results on Monday, March 18th. The biotechnology company reported ($0.80) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.80).
A number of equities analysts have recently weighed in on ALPN shares. Zacks Investment Research raised Alpine Immune Sciences from a “hold” rating to a “buy” rating and set a $7.00 target price on the stock in a research report on Thursday, January 24th. Oppenheimer set a $13.00 price target on Alpine Immune Sciences and gave the company a “buy” rating in a research report on Tuesday, March 19th. ValuEngine raised Alpine Immune Sciences from a “sell” rating to a “hold” rating in a research report on Tuesday, March 5th. Finally, reissued a “buy” rating and issued a $13.00 price target on shares of Alpine Immune Sciences in a research report on Tuesday, February 12th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Alpine Immune Sciences currently has an average rating of “Buy” and a consensus target price of $12.07.
ALPN stock traded down $0.14 during trading on Tuesday, hitting $6.29. The company had a trading volume of 190 shares, compared to its average volume of 11,904. Alpine Immune Sciences has a one year low of $3.66 and a one year high of $10.57. The stock has a market capitalization of $87.12 million, a PE ratio of -2.39 and a beta of 2.06. The company has a debt-to-equity ratio of 0.05, a current ratio of 6.59 and a quick ratio of 6.59.
In other news, major shareholder Tiger Management L.L.C. sold 25,000 shares of the business’s stock in a transaction on Friday, February 8th. The stock was sold at an average price of $5.85, for a total value of $146,250.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 69.00% of the stock is owned by insiders.
A number of institutional investors and hedge funds have recently modified their holdings of ALPN. Vanguard Group Inc. increased its position in Alpine Immune Sciences by 5.2% in the third quarter. Vanguard Group Inc. now owns 227,834 shares of the biotechnology company’s stock worth $1,442,000 after buying an additional 11,200 shares in the last quarter. Vanguard Group Inc boosted its stake in shares of Alpine Immune Sciences by 5.2% in the third quarter. Vanguard Group Inc now owns 227,834 shares of the biotechnology company’s stock worth $1,442,000 after acquiring an additional 11,200 shares during the period. Hikari Power Ltd bought a new position in shares of Alpine Immune Sciences in the fourth quarter worth about $453,000. Victory Capital Management Inc. boosted its stake in shares of Alpine Immune Sciences by 109.0% in the fourth quarter. Victory Capital Management Inc. now owns 136,072 shares of the biotechnology company’s stock worth $501,000 after acquiring an additional 70,980 shares during the period. Finally, Raymond James & Associates bought a new position in shares of Alpine Immune Sciences in the first quarter worth about $94,000. Institutional investors and hedge funds own 53.79% of the company’s stock.
About Alpine Immune Sciences
Alpine Immune Sciences, Inc focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an ICOS/CD28 antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202 program for the treatment of cancer.
Featured Story: How liquidity affects the bid-ask spread
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with MarketBeat.com's FREE daily email newsletter.